Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natalizumab - Biogen/Perrigo

Next Previous
X
Search
Drug Profile

Natalizumab - Biogen/Perrigo

Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody - Biogen/Perrigo; BG-00002; BG-0002; BG-0002-E; Tysabri

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Corporation
  • Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
  • Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Multiple sclerosis
  • Phase II Graft-versus-host disease
  • Discontinued Epilepsy; Multiple myeloma; Rheumatoid arthritis; Stroke

Most Recent Events

  • 27 May 2024 Biogen terminates a Phase-III clinical trials in Multiple sclerosis in Japan (SC) due to sponsors decision (NCT05265728)
  • 11 Oct 2023 Adverse events data from the phase III NOVA trial in Multiple sclerosis were presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS)
  • 24 Jul 2023 Biogen completes the phase-IIIb NOVA trial in Multiple Sclerosis in USA, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain and the UK (SC; IV) (NCT03689972)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top